Lowering B-type Natriuretic Peptide Levels and Increasing Cardiac Function: the Role of Levosimendan in the Treatment of Heart Failure

Overview

Journal J Int Med Res

Publisher Sage Publications

Date 2025 Feb 8

PMID 39922797

Authors

Jianfeng Meng

Ye Zuo

Affiliations

Soon will be listed here.

Abstract

Objective: In this study, we examined whether levosimendan could lower B-type natriuretic peptide (BNP) and improve cardiac function in patients with heart failure who have diuretic resistance and low ejection fraction.

Methods: We conducted a cohort study among 120 participants from September 2022 to August 2023. We investigated the efficacy of treatment with levosimendan in patients with HF who exhibited diuretic resistance and had a low ejection fraction. All patients received recombinant human neuronal natriuretic peptide (rhBNP) and the treatment group additionally received levosimendan. In addition to the primary endpoints, safety measures were assessed, encompassing the monitoring of blood pressure, heart rate, and serum creatinine levels.

Results: Patients in the treatment and control groups were similar in age, sickness duration, weight, and sex ratio. Medication use, New York Heart Association classification, ejection fraction percentage, and other factors were evenly distributed. The treatment group showed increased urine volume and weight loss. Both groups had similar post-treatment systolic blood pressure, heart rate, and serum creatinine levels, indicating good safety.

Conclusion: Levosimendan in combination with rhBNP may improve diuretic resistance in patients with HF and low ejection fraction. Further multicenter trials are needed to confirm our findings.

References

Savarese G, Lund L . Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1):7-11. PMC: 5494150. DOI: 10.15420/cfr.2016:25:2. View

Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C . Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther. 2007; 114(2):184-97. DOI: 10.1016/j.pharmthera.2007.01.008. View

Oner E, Erturk M, Birant A, Mansiroglu A, Akturk I, Karakurt H . Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure. Cardiol J. 2014; 22(1):87-93. DOI: 10.5603/CJ.a2014.0044. View

Del Ry S, Cabiati M, Clerico A . Natriuretic peptide system and the heart. Front Horm Res. 2014; 43:134-43. DOI: 10.1159/000360597. View

Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A . Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract. 2007; 62(2):228-33. DOI: 10.1111/j.1742-1241.2007.01510.x. View

Nieminen M, Akkila J, Hasenfuss G, Kleber F, Lehtonen L, Mitrovic V . Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36(6):1903-12. DOI: 10.1016/s0735-1097(00)00961-x. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Huffman M, Prabhakaran D . Heart failure: epidemiology and prevention in India. Natl Med J India. 2011; 23(5):283-8. PMC: 3913650. View

Sabatasso S, Vaucher P, Augsburger M, Donze N, Mangin P, Michaud K . Sensitivity and specificity of NT-proBNP to detect heart failure at post mortem examination. Int J Legal Med. 2011; 125(6):849-56. PMC: 3192281. DOI: 10.1007/s00414-011-0581-6. View

10.

Palmiere C, Tettamanti C, Bonsignore A, De Stefano F, Vanhaebost J, Rousseau G . Cardiac troponins and NT-proBNP in the forensic setting: Overview of sampling site, postmortem interval, cardiopulmonary resuscitation, and review of the literature. Forensic Sci Int. 2017; 282:211-218. DOI: 10.1016/j.forsciint.2017.11.034. View

11.

Nohria A, Mielniczuk L, Stevenson L . Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005; 96(6A):32G-40G. DOI: 10.1016/j.amjcard.2005.07.019. View

12.

Slawsky M, Colucci W, Gottlieb S, GREENBERG B, Haeusslein E, Hare J . Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000; 102(18):2222-7. DOI: 10.1161/01.cir.102.18.2222. View

13.

Bloom M, Greenberg B, Jaarsma T, Januzzi J, Lam C, Maggioni A . Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017; 3:17058. DOI: 10.1038/nrdp.2017.58. View

14.

Zhu B, Ishikawa T, Michiue T, Li D, Zhao D, Tanaka S . Postmortem pericardial natriuretic peptides as markers of cardiac function in medico-legal autopsies. Int J Legal Med. 2006; 121(1):28-35. DOI: 10.1007/s00414-006-0102-1. View

15.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D . Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. J Cardiovasc Pharmacol. 2020; 76(1):4-22. PMC: 7340234. DOI: 10.1097/FJC.0000000000000859. View

16.

De Luca L, Colucci W, Nieminen M, Massie B, Gheorghiade M . Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006; 27(16):1908-20. DOI: 10.1093/eurheartj/ehi875. View

17.

Benjamin E, Blaha M, Chiuve S, Cushman M, Das S, Deo R . Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017; 135(10):e146-e603. PMC: 5408160. DOI: 10.1161/CIR.0000000000000485. View

18.

Liu G, Lin X . Effect of Levosimendan on B-type Natriuretic Peptide Levels in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Altern Ther Health Med. 2023; 29(7):184-190. View

19.

Parissis J, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K . Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006; 98(11):1489-92. DOI: 10.1016/j.amjcard.2006.06.052. View

20.

Cao Z, Xue J, Zhang Y, Tian M, Xiao Y, Jia Y . Differential expression of B-type natriuretic peptide between left and right ventricles, with particular regard to sudden cardiac death. Mol Med Rep. 2017; 16(4):4763-4769. PMC: 5647027. DOI: 10.3892/mmr.2017.7136. View